Opioid rotation in patients with cancer pain: A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine

Cancer

Volumn 78, Issue 4, 1996, Pages 852-857

  Bruera, Eduardo ^a   Pereira, Jose ^b   Watanabe, Sharon ^b   Belzile, Michelle ^b   Kuehn, Norma ^b   Hanson, John ^b  

^a GREY NUNS COMMUNITY HOSPITAL   (Canada)

^b NONE

Author keywords

equianalgesic dose tables; hydromorphone; methadone; morphine; opioid rotations; retrospective study

Indexed keywords

HYDROMORPHONE; METHADONE; MORPHINE; NALOXONE; OPIATE;

ADULT; AGED; ANALGESIA; ARTICLE; BIOEQUIVALENCE; CANCER PAIN; CANCER PALLIATIVE THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECTAL DRUG ADMINISTRATION; RESPIRATION DEPRESSION; SEDATION; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYDROMORPHONE; INJECTIONS, SUBCUTANEOUS; MALE; METHADONE; MIDDLE AGED; MORPHINE; NEOPLASMS; PAIN; RETROSPECTIVE STUDIES;

EID: 0029758390     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T     Document Type: Article

References (27)

1. Foley K. The treatment of cancer pain. N Engl J Med 1985;313:84-95.
2. Cancer Pain Relief. Geneva, Switzerland: World Health Organization, 1986:19.
3. Ellison NM. Opioid analgesics for cancer pain: toxicities and their treatments. In: Patt RB, editor. Cancer Pain. Philadelphia: JB Lippincott Company, 1993:185-94.
4. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation (OR) for toxicity reduction in terminal cancer patients. J Pain Symptom Manag 1995;10(5):378-84.
5. Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration and opiate rotation. J Pain Symptom Manag 1995;10(4):287-91.
6. Fainsinger R, Schoeller T, Bruera E. Methadone in the management of cancer pain: a review. Pain 1993;52:137-47.
7. Bruera E, Watanabe S, Fainsinger RL, Spachynski K, Suarez-Almazor M, Inturrisi C. Custom-made capsules and suppositories of methadone for patients on high dose opioids for cancer pain. Pain 1995;62:141-6.
8. Management of Cancer Pain. Clinical Practice Guidelines. Rockville (MD): U.S. Department of Health and Human Services, 1994 AHCPR Pub No. 94-0592.
9. Cancer pain: a monograph on the management of cancer pain. Ottawa: Health & Welfare Canada: Minister of Supply and Services, Canada, H42-2/5, 1984E.
10. Twycross R, Lack S. Pain Relief. In: Twycross R, Lack S, Eds. Therapeutics in Terminal Cancer, 2nd Edition. Edinburgh: Churchill Livingston 1990;2:11-39.
11. Levy M. Pain management in advanced cancer. Semin Oncol 1985;12(4):394-410.
12. Bonica J, Ventafridda V. Cancer Pain. In: Bonica J, Ed. The Management of Pain, 2nd Edition. Philadelphia: Lea and Febiger, 1990;4:400-460.
13. Shott S. Hypothesis testing: computer output for t test. In: S. Shott, Ed. Statistics for Health Professionals. Philadelphia: W.B. Saunders Company, 1990;7.8:125-7.
14. Thomas Z, Bruera E. Use of methadone in a highly tolerant patient receiving parenteral hydromorphone. J Pain Symptom Manag 1995;10(4):315-7.
15. MacDonald N, Der L, Allan S, Champion P. Opioid excitability: the application of alternate opioid therapy. Pain 1993;53:353-5.
16. Galer BS, Coyle N, Pasternak GW. Individual variability in response to different opioids; report of five cases. Pain 1992;49:87-91.
17. Twycross RG. A comparison of diamorphine with lidocaine and methadone. Br J Clin Pharmacol 1977;4:691-3.
18. Beaver WT, Wallenstein SL, Houde RW. A clinical comparison of the analgesic effects of methadone and morphine administered intramuscularly and of orally and parenterally administered methadone. Clin Pharmacol Ther 1967;8:415-26.
19. Inturrisi CE. Management of cancer pain. Pharmacology and principles of management. Cancer 1989;63:2308-20.
20. Houde RW, Wallenstein SL, Beaver WT. Evaluation of analgesics in patients with caner pain. In: Lasagna L, editor. International encyclopedia of pharmacology and therapeutics. Section 6. Clinical pharmacology. Volume 1. New York: Pergamon Press, 1966:59-97.
21. Bruera E, Schoeller T, Montejo G. Organic hallucinosis in patients receiving high doses of opiates for cancer pain. Pain 1992;48:397-9.
22. Sjogren P, Dragsted L, Christensen CB. Myoclonic spasms during treatment with high doses of intravenous morphine in renal failure. Acta Anaesthesiol Scand 1993;37:780-2.
23. Hagen N, Swanson R. Multifocal myoclonus and seizures in extremely high dose opioid administration. In: Proceedings of American Academy of Neurology, New York, NY, April 29, 1993.
24. Babul N, Darke AC. Putative role of hydromorphone metabolites in myoclonus. Pain 1992;51:260-1.
25. Hagen N, Thirlwell M, Dhaliwal HS, Babul N, Harsanyi Z, Darke AC. Steady-state pharmacokinetics of hydromorphone and hydromorphone-3-glurcuronide in cancer patients after immediate and controlled-release hydromorphone. J Clin Pharmacol 1995;35:37-44.
26. Max M, Portenoy R. Pain research: designing clinical trials in palliative care. In: Doyle D, Hanks G, MacDonald N, editors. Oxford textbook of palliative medicine. Oxford: Oxford University Press, 1993;3.2:77-86.
27. Max MB, Laska EM. Single-dose analgesic comparisons. In: Max MAB, Portenoy RK, Laska EM, editors . The design of analgesic clinical trials. New York: Raven Press, 1991:55-95.